Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients

OBJECTIVE: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on multicolor fluorescence in situ hybridization (FISH). It has been used successfully in the USA following its Food and Drug Administration approval in 2001. However, the technology was not approved for use in Japan until 2017. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Takashi, Okamura, Takehiko, Yanase, Takahiro, Chaya, Ryosuke, Moritoki, Yoshinobu, Kobayashi, Daichi, Akita, Hidetoshi, Yasui, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948889/
https://www.ncbi.nlm.nih.gov/pubmed/31030505
http://dx.doi.org/10.31557/APJCP.2019.20.4.1271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948889/
https://www.ncbi.nlm.nih.gov/pubmed/31030505
http://dx.doi.org/10.31557/APJCP.2019.20.4.1271

Ejemplares similares